Coherus Oncology, Inc.
NASDAQ:CHRSBiotechnology
+$0.03 today
- Market cap
- $63.35M
- Beta
- 0.96
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.11
Volume 2.55M
Average 1.15M
CHRS Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Coherus Oncology, Inc.NASDAQ: CHRS
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 39.8% from a year ago
Cash & equivalents stood at $115.24M at the end of Q1 FY2026, up 39.8% from a year earlier and up 29.7% from the prior quarter. Over 3 fiscal years it compounded at +11.8% a year.
Context
- Cash & equivalents amounted to 43.3% of total assets at the end of Q1 FY2026, up 21.1 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +39.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 88.88M USD
- Year-over-year change
- -29.5%
- 4-year CAGR
- -32.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 88.88M | -29.5% |
| FY2024 | 2024-12-31 | 125.99M | +22.4% |
| FY2023 | 2023-12-31 | 102.89M | +61.9% |
| FY2022 | 2022-12-31 | 63.55M | -84.8% |
| FY2021 | 2021-12-31 | 417.2M | — |
Cash & Equivalents vs competitors
How CHRS compares with its peers on the latest reported figures
- CHRS's Mar 2026 cash & equivalents of $115.24M is the 3rd highest of the 11 companies compared; the peer median is $33.02M.
- Its year-over-year change of +39.8% is the 6th highest of 11, against a peer median of +60.7%.
- Cash & equivalents amounts to 43.3% of total assets for CHRS, versus a peer median of 34.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $184.15M | +283.0% | +35.0% | 76.2% | |
| Sep 2026 | $134.71M | +203.3% | +61.3% | 95.5% | |
| Mar 2026 | $115.24M | +39.8% | +11.8% | 43.3% | |
| Mar 2026 | $61.27M | +19.5% | +35.9% | 18.6% | |
| Mar 2026 | $41.71M | +114.4% | -5.0% | 40.8% | |
| Mar 2026 | $37M | +102.0% | -23.6% | 28.6% | |
| Mar 2026 | $29.05M | +166.7% | -8.6% | 9.9% | |
IMDXInsight Molecular Diagnostics Inc. | Mar 2026 | $28.2M | -9.1% | -16.6% | 69.8% |
| Mar 2026 | $27.59M | +9.6% | -40.7% | 46.0% | |
| Mar 2026 | $24.99M | -80.0% | +6.4% | 25.0% | |
| Mar 2026 | $14.74M | -83.9% | +27.2% | 7.7% | |
| Peer median (excluding CHRS) | $33.02M | +60.7% | +0.7% | 34.7% | |
Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 417.2M | 63.55M | 102.89M | 125.99M | 88.88M |
| Short-term Investments | 0 | 128.13M | 14.86M | 0 | 83.25M |
| Net Receivables | 123.02M | 109.96M | 260.52M | 122.33M | 18.42M |
| Inventory | 37.64M | 38.79M | 62.61M | 70.09M | 3.17M |
| Other Current Assets | 10.8M | 22.92M | 11.1M | 11.53M | 6.23M |
| Total Current Assets | 602.32M | 381.23M | 475.63M | 341.58M | 206.71M |
| Property, Plant & Equipment (Net) | 7.81M | 8.75M | 5.12M | 2.84M | 1.35M |
| Goodwill | 943K | 943K | 943K | 0 | 0 |
| Intangible Assets | 2.62M | 4.99M | 70.73M | 53.65M | 46.24M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 65.64M | 84.93M | 77.18M | 50.47M | 4.05M |
| Total Non-current Assets | 77.01M | 99.61M | 153.97M | 106.95M | 51.64M |
| Total Assets | 679.33M | 480.85M | 629.6M | 448.53M | 258.34M |
| Account Payables | 16.16M | 11.53M | 35.22M | 28.46M | 9.92M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 22.01M | 22.61M | 21.52M | 33.11M | 16.07M |
| Total Current Liabilities | 165.33M | 138.69M | 331.77M | 282.98M | 141.88M |
| Long-term Debt | 408.28M | 471.06M | 473.37M | 264.93M | 37.05M |
| Deferred Tax Liabilities | 0 | 0 | 1.1M | 1.1M | 1.1M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 750K | 3.47M | 11.46M | 28.23M | 15.84M |
| Total Non-current Liabilities | 416.28M | 479.57M | 491.26M | 297.54M | 55.45M |
| Total Liabilities | 581.61M | 618.27M | 823.03M | 580.52M | 197.33M |
| Common Stock | 7K | 8K | 11K | 12K | 12K |
| Retained Earnings | (1.05B) | (1.34B) | (1.58B) | (1.55B) | (1.38B) |
| Accumulated OCI | (270K) | (249K) | (248K) | (275K) | (195K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 97.73M | (137.42M) | (193.43M) | (131.99M) | 61.01M |
| Total Debt | 419.02M | 480.42M | 480.84M | 269.9M | 40.34M |
| Net Debt | 1.83M | 416.88M | 377.95M | 143.92M | (48.54M) |
Coherus Oncology, Inc.
NASDAQ:CHRS
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.